Journal Article

Testing a new platform to screen disease-modifying therapy in type 1 diabetes

Bahnson, Henry T., Lord, Sandra M., Greenbaum, Carla J., Liljenquist, David R., Virostko, John, Speake, Cate

2023

Overview

Studies of new therapies to preserve insulin secretion in early type 1 diabetes require several years to recruit eligible subjects and to see a treatment effect; thus, there is interest in alternative study designs to speed this process. Most people with longstanding type 1 diabetes no longer secrete insulin. However, studies from pancreata of those with longstanding T1D show that beta cells staining for insulin can persist for decades after diagnosis, and this is paralleled in work showing proinsulin secretion in individuals with longstanding disease; collectively this suggests that there is a reserve of alive but “sleeping” beta cells. Here, we designed a novel clinical trial platform to test whether a short course of therapy with an agent known to have effects in type 1 diabetes with residual endogenous insulin could transiently induce insulin secretion in those who no longer produce insulin. A therapy that transiently “wakes up” sleeping beta cells might be tested next in a fully powered trial in those with endogenous insulin secretion. In this three-arm non-randomized pilot study, we tested three therapies known to impact disease: two beta-cell supportive agents, liraglutide and verapamil, and an immunomodulatory agent, golimumab. The golimumab treated arm was not fully enrolled due to uncertainties about immunotherapy during the COVID-19 pandemic. Participants had mixed-meal tolerance test (MMTT)-stimulated C-peptide below the quantitation limit (<0.02 ng/mL) at enrollment and received 8 to 12 weeks of therapy. At the completion of therapy, none of the individuals achieved the primary outcome of MMTT-stimulated C-peptide ≥ 0.02 ng/mL. An exploratory outcome of the verapamil arm was MRI-assessed pancreas size, diffusion, and longitudinal relaxation time, which showed repeatability of these measures but no treatment effect. The liraglutide and golimumab arms were registered on clinicaltrials.gov under accession number NCT03632759 and the verapamil arm under accession number NCT05847413. Trail registration: Protocols are registered in ClinicalTrials.gov under accession numbers NCT03632759 and NCT05847413 .

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Beta cells / Biology and Life Sciences / C-Peptide / Care and treatment / Clinical trials / COVID-19 / Diabetes / Diabetes mellitus (insulin dependent) / Diabetes Mellitus, Type 1 - drug therapy / Diabetes therapy / Diagnosis / Diagnostic imaging / Evaluation / Health services / Humans / Hypoglycemic agents / Immunomodulation / Immunotherapy / Insulin / Insulin - therapeutic use / Insulin secretion / Liraglutide / Medical screening / Medicine and Health Sciences / Methods / Monoclonal antibodies / Pandemics / Peptides / Physical Sciences / Pilot Projects / Relaxation time / Research and Analysis Methods / Research centers / Therapy / Type 1 diabetes / Type 2 diabetes / Verapamil